1. Academic Validation
  2. Non-Covalent Albumin Ligands in FDA-Approved Therapeutic Peptides and Proteins

Non-Covalent Albumin Ligands in FDA-Approved Therapeutic Peptides and Proteins

  • J Med Chem. 2023 Mar 23;66(6):3656-3663. doi: 10.1021/acs.jmedchem.2c01021.
Florencio Zaragoza 1
Affiliations

Affiliation

  • 1 Novo Nordisk A/S, Novo Nordisk Park, Måløv DK-2760, Denmark.
Abstract

An increasing number of drugs that consist of a therapeutic peptide or protein linked to an albumin-binding structure are being approved. In this perspective, the pharmacokinetic data of currently marketed drugs of this type will be presented. Acylation with fatty acids or fatty α,ω-dicarboxylic acids has been used successfully to prepare long-acting analogs of Insulin, GLP-1, and other Peptides but not of larger proteins. With a tetrazole-sulfonylamide fatty acid bioisostere, it has now been possible to prepare a long-acting analog of human growth hormone (191 Amino acids), which is suitable for once-weekly administration.

Figures
Products